COSMIC-021 is a clinical trial platform testing the combination of the MET/VEGF/TAM kinase inhibitor cabozantinib in combination with the anti-PD-L1 drug atezolizumab, which demonstrated encouraging clinical activity in tumor types including renal cell carcinoma, urothelial carcinoma, prostate cancer, lung cancer, and hepatocellular carcinoma
At ESMO 2020, Dr. Pal shared data from a cohort of COSMIC-021 (NCT03170960) examining the efficacy and safety of this drug combination in previously untreated patients with advanced clear-cell renal cell carcinoma (ccRCC). The study design is as follows:
|